Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 4/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595723 | 0.91 | KCNQ2 (0.38) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3592392 | 0.91 | KCNQ2 (0.38) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3597665 | 0.89 | POLB (0.33) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3598141 | 0.88 | L3MBTL1 (0.35) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3595273 | 0.88 | L3MBTL1 (0.35) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3590832 | 0.88 | L3MBTL1 (0.35) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3591303 | 0.87 | L3MBTL1 (0.34) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3598682 | 0.87 | L3MBTL1 (0.34) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3605705 | 0.86 | L3MBTL1 (0.35) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL3601712 | 0.85 | L3MBTL1 (0.32) | KCNQ2KCNQ3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | KCNQ2 630/4885KCNQ3 1050/4885L3MBTL1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.